• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Moderna Inc (NQ: MRNA )

    63.93 -2.90 (-4.34%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,609,262
    Open 67.13
    Bid (Size) 64.00 (1)
    Ask (Size) 64.15 (1)
    Prev. Close 66.83
    Today's Range 63.41 - 67.55
    52wk Range 62.55 - 170.47
    Shares Outstanding 384,000,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    The Covid Era Tech Promises To Reinvent Cancer Treatment
    Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story. 
    Via Benzinga
    Exposures COVID-19
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Performance

    YTD
    -43.17%
    -43.17%
    1 Month
    -12.35%
    -12.35%
    3 Month
    -44.86%
    -44.86%
    6 Month
    -39.46%
    -39.46%
    1 Year
    -38.12%
    -38.12%

    More News

    Read More
    Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
    Via ACCESSWIRE
    MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    Here's How Much $100 Invested In Moderna 5 Years Ago Would Be Worth Today
    Via Benzinga
    Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
    Via ACCESSWIRE
    3 Surprisingly Underrated Stocks to Buy Right Now
    Via The Motley Fool
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Top 3 Health Care Stocks That May Explode This Month
    Via Benzinga
    2 Beaten-Down Stocks to Buy and Hold for a Decade
    Via The Motley Fool
    MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Pfizer Advances On Its Cancer Journey
    Via Benzinga
    Down 13% in 1 Day, Is Moderna Stock in Trouble?
    Via The Motley Fool
    3 Beaten-Down Stocks Ready for a Comeback
    Via MarketBeat
    Topics Economy
    Exposures Economy
    Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
    Via The Motley Fool
    Moderna, Inc. REMINDER – MRNA Stockholders Should Contact Robbins LLP for Information About the Moderna, Inc. Class Action and Pending Lead Plaintiff Deadline
    From Robbins LLP
    Via GlobeNewswire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
    Via Benzinga
    Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
    Via The Motley Fool
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    S&P 500 Briefly Hits Record High Just Ahead Of Fed Rate Cut, Extends 7-Day Winning Streak: Tuesday's Top 5 Gainers
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Momentum Investing Gives You An Edge, Until It Doesn’t
    Via Talk Markets
    Small Caps, Bitcoin Rally As Traders Await Fed Rate Cut; Treasury Yields, US Dollar Tick Up On Strong Retail Sales: What's Driving Markets Tuesday?
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.